| Document Date: 2015-02-26 12:17:24
Open Document File Size: 245,12 KBShare Result on Facebook
City VANCOUVER / / Company Combined Company / Greenhill & Co. / QLT Holding Corp. / Novartis AG / Tolmar Therapeutics Inc. / Endo International plc / QLT Inc. / Auxilium On October / QLT Acquisition Corp. / Credit Suisse Securities (USA) LLC / Passive Foreign Investment Company / Toronto Stock Exchange / NASDAQ Stock Market / / Country United States / Canada / / Currency USD / / / Event M&A / Reorganization / Earnings Announcement / FDA Phase / Product Issues / / IndustryTerm indirect wholly-owned subsidiary / biotechnology / treatment of certain inherited retinal diseases / proposed pivotal trial protocol / ocular products / / MedicalCondition Retinitis Pigmentosa / Congenital Amaurosis / certain inherited retinal diseases / Leber Congenital Amaurosis / Inherited Retinal Disease / / MedicalTreatment retreatment / / Organization European Medicines Agency / U.S. Food and Drug Administration / U.S. Securities and Exchange Commission / / Person Andrea Rabney / / / Position financial advisor / advisor / general economic conditions / General / Private / head / / Product Visudyne / Eligard / Leber Congenital Amaurosis / dark adaptation / EMA / QLT091001 / / Technology biotechnology / proposed pivotal trial protocol / / URL www.qltinc.com / /
SocialTag |
News release QLT ANNOUNCES FOURTH QUARTER AND YEAR END 2014 RESULTS Provides Strategic Review and Synthetic Retinoid Program Update For Immediate Release February 26, 2015